James C. Keith, Jr., D.V.M., Ph.D.
Dr. Keith is Founder and Senior Consultant at Keith Pharmacology Research Group, LLC since it's creation in 2011. As a pharmacologist with over 40 years of experience in Comparative Medicine, Animal Models of Human Disease, Pharmacology Research, Drug Discovery, Preclinical Research and Drug Development, he has always focused on Development of Novel Therapeutics for Diseases with High Unmet Medical Need.
An author or co-author of over 147 peer-reviewed papers and book chapters, he serves as inventor or co-inventor on 31 issued US and International patents, and is a member of numerous professional organizations, including the American Heart Association, the American Physiological Society, the American Veterinary Medical Association, the Royal Society of Medicine (London)-Fellow, and the International Society for the Study of Hypertension in Pregnancy.
Specialties: Pharmacology Research, Comparative Medicine, Animal Models of Human Disease, Vascular Biology and Inflammation, Hypertension of Pregnancy, Histology and Electron Microscopy, Quantitative Imaging Biomarkers
Before forming Keith Pharmacology Research Group, LLC, Dr. Keith worked at Genetics Institute / Wyeth Research / Pfizer, and achieving the title of Distinguished Research Fellow (2006 – 2011), after starting his career at Genetics Institute as a Senior Principal Scientist and Lab Head of the Animal Models Laboratory in Preclinical Research. His laboratories conducted animal model studies defining biologic activities, biomarkers of efficacy and safety, and minimum effective doses of cardiovascular, inflammatory disease drug candidate molecules, recombinant human cytokines, and recombinant human therapeutic proteins for hemophilia. The pharmacology research and development contributed to the approval of Neumega, BeneFIX, ReFacto (Europe), ReFacto (US), and Xyntha. Prior to entering the pharmaceutical industry, Dr. Keith served 11 years as an Assistant and Associate Professor of Veterinary Medicine at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech. It was there that the research on atherosclerosis continued and the new area of interest concerning the pathophysiology of preeclampsia emerged.
Dr. Keith earned his PhD at the University of Georgia in Physiology and Pharmacology for his work concerning the response to injury hypothesis of atherogenesis and low-dose aspirin therapy for prevention or regression of vascular injury-induced arteriosclerosis. He received both his D.V.M. and B.S. degree from the University of Tennessee in Knoxville.
An author or co-author of over 147 peer-reviewed papers and book chapters, he serves as inventor or co-inventor on 31 issued US and International patents, and is a member of numerous professional organizations, including the American Heart Association, the American Physiological Society, the American Veterinary Medical Association, the Royal Society of Medicine (London)-Fellow, and the International Society for the Study of Hypertension in Pregnancy.
Specialties: Pharmacology Research, Comparative Medicine, Animal Models of Human Disease, Vascular Biology and Inflammation, Hypertension of Pregnancy, Histology and Electron Microscopy, Quantitative Imaging Biomarkers
Before forming Keith Pharmacology Research Group, LLC, Dr. Keith worked at Genetics Institute / Wyeth Research / Pfizer, and achieving the title of Distinguished Research Fellow (2006 – 2011), after starting his career at Genetics Institute as a Senior Principal Scientist and Lab Head of the Animal Models Laboratory in Preclinical Research. His laboratories conducted animal model studies defining biologic activities, biomarkers of efficacy and safety, and minimum effective doses of cardiovascular, inflammatory disease drug candidate molecules, recombinant human cytokines, and recombinant human therapeutic proteins for hemophilia. The pharmacology research and development contributed to the approval of Neumega, BeneFIX, ReFacto (Europe), ReFacto (US), and Xyntha. Prior to entering the pharmaceutical industry, Dr. Keith served 11 years as an Assistant and Associate Professor of Veterinary Medicine at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech. It was there that the research on atherosclerosis continued and the new area of interest concerning the pathophysiology of preeclampsia emerged.
Dr. Keith earned his PhD at the University of Georgia in Physiology and Pharmacology for his work concerning the response to injury hypothesis of atherogenesis and low-dose aspirin therapy for prevention or regression of vascular injury-induced arteriosclerosis. He received both his D.V.M. and B.S. degree from the University of Tennessee in Knoxville.